Compare Sunbelt Rentals Holdings Inc. Common Stock (SUNB) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sunbelt Rentals Holdings Inc. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Sunbelt Rentals Holdings Inc. Common Stock trades at $74.7 (market cap $31.69B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Sunbelt Rentals Holdings Inc. Common Stock is far larger — about 4.2× Spyre Therapeutics Inc. Common Stock's market cap, and Sunbelt Rentals Holdings Inc. Common Stock pays a 1.36% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sunbelt Rentals Holdings Inc. Common Stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SUNB | SYRE | |
|---|---|---|
Market Cap | $31.69B | $7.52B |
Volume | 3,330,792 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $86.06 | $108.92 |
52-Week Low | $63.09 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $43.08B | $6.52B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SUNB trades at $77.33, up 2.34% with neutral technical signals. The company reported strong Q2 2026 earnings beat ($1.18 vs $0.99 expected) and raised FY2027 guidance. Valuation metrics show P/E of 23.08 and ROE of 18.37%, with revenue growth from $10.79B to $11.5B projected. Recent institutional buying includes State Street Corp's $441M investment in Q2 2026.
Outlook remains positive with analyst consensus target of $86.83 (12.3% upside). Key opportunities include infrastructure demand and specialty equipment rental growth, while risks involve significant debt load ($7.5B) and declining free cash flow. The stock presents a balanced risk-reward profile with moderate growth potential.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sunbelt Rentals Holdings Inc. Common Stock
Sunbelt Rentals provides equipment rentals and related services in the United States, Canada, and the United Kingdom. Its fleet includes general and specialty equipment for construction, industrial, infrastructure, and maintenance projects.
Read more on SUNB →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
